No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors

Molecular Pharmaceutics

Volumn 9, Issue 6, 2012, Pages 1693-1704

  Martinez Becerra, P ^a   Vaquero, J ^a   Romero, M R ^a,f   Lozano, E ^a   Anadon, C ^a   MacIas, R I R ^a,f   Serrano, M A ^a,f   Grane Boladeras N ^b,f   Munoz Bellvis L ^c   Alvarez, L ^d   Sangro, B ^e,f   Pastor Anglada, M ^b,f   Marin, J J G ^a,f  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

apoptosis; cancer; drug; metabolism; mutation; pharmacology; refractoriness; transport

Indexed keywords

CISPLATIN; CYTOCHROME P450 2A1; FARNESOID X RECEPTOR; ISOPROTEIN; ORGANIC CATION TRANSPORTER 1; PROTEIN BIRC5; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER SURGERY; CARCINOMA CELL; CELL STRAIN HEPG2; CELL SURVIVAL; CONTROLLED STUDY; DRUG METABOLISM; DRUG UPTAKE; EFFUSION; FEMALE; GENE EXPRESSION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; CISPLATIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HEP G2 CELLS; HEPATOBLASTOMA; HUMANS; LIVER; LIVER NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84862026667     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300028a     Document Type: Article

References (43)

1. Marin, J. J.; Romero, M. R.; Martinez-Becerra, P.; Herraez, E.; Briz, O. Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. Curr. Mol. Med. 2009, 9 (9), 1108-29.
2. Marin, J. J.; Castano, B.; Blazquez, A. G.; Rosales, R.; Efferth, T.; Monte, M. J. Strategies for overcoming chemotherapy resistance in enterohepatic tumours. Curr. Mol. Med. 2010, 10 (5), 467-85.
3. Kemper, J. K. Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications. Biochim. Biophys. Acta 2011, 1812 (8), 842-50.
4. Monte, M. J.; Serrano, M. A.; Herraez, E.; Vaquero, J.; Gonzalez-Sanchez, E.; Romero, M. R.; Rosales, R. R.; Blazquez, A. G.; Perez, M. J.; Macias, R. I. R.; Sanchez-Vicente, L.; Lozano, E.; Jimenez, F.; Gonzalez-San Martin, F.; Muntane, J.; Briz, O.; Marin, J. J. G. Chemoresistance can be induced by bile acid-independent activation of FXR in liver and intestinal cancer cells. Hepatology 2011, 54 (4(S)), 713-4.
5. Eloranta, J. J.; Kullak-Ublick, G. A. The role of FXR in disorders of bile acid homeostasis. Physiology (Bethesda) 2008, 23, 286-95.
6. Macias, R. I.; Hierro, C.; Cuesta de Juan, S.; Jimenez, F.; Gonzalez-San Martin, F.; Marin, J. J. Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases. Br. J. Nutr. 2011, 1-12.
7. Tusher, V. G.; Tibshirani, R.; Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (9), 5116-21. (Pubitemid 32397092)
8. Saeed, A. I.; Bhagabati, N. K.; Braisted, J. C.; Liang, W.; Sharov, V.; Howe, E. A.; Li, J.; Thiagarajan, M.; White, J. A.; Quackenbush, J. TM4 microarray software suite. Methods Enzymol. 2006, 411, 134-93.
9. Huang, Y.; Sadee, W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 2006, 239 (2), 168-82. (Pubitemid 43996825)
10. Marin, J. J.; Romero, M. R.; Briz, O. Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr. Med. Chem. 2010, 17 (8), 709-40.
11. Kinoshita, M.; Miyata, M. Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci. Hepatology 2002, 36 (2), 433-8. (Pubitemid 34810364)
12. Vavricka, S. R.; Jung, D.; Fried, M.; Grutzner, U.; Meier, P. J.; Kullak-Ublick, G. A. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J. Hepatol. 2004, 40 (2), 212-8. (Pubitemid 38115824)
13. Zollner, G.; Wagner, M.; Fickert, P.; Silbert, D.; Fuchsbichler, A.; Zatloukal, K.; Denk, H.; Trauner, M. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 2005, 25 (2), 367-79.
14. Garcia-Manteiga, J.; Molina-Arcas, M.; Casado, F. J.; Mazo, A.; Pastor-Anglada, M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin. Cancer Res. 2003, 9 (13), 5000-8. (Pubitemid 37323307)
15. Holzer, A. K.; Samimi, G.; Katano, K.; Naerdemann, W.; Lin, X.; Safaei, R.; Howell, S. B. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 2004, 66 (4), 817-23. (Pubitemid 39319453)
16. Chan, L. M.; Lowes, S.; Hirst, B. H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 2004, 21 (1), 25-51. (Pubitemid 38050202)
17. Cho, C. W.; Liu, Y.; Yan, X.; Henthorn, T.; Ng, K. Y. Carrier-mediated uptake of rhodamine 123: implications on its use for MDR research. Biochem. Biophys. Res. Commun. 2000, 279 (1), 124-30.
18. Safaei, R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett. 2006, 234 (1), 34-9. (Pubitemid 43343939)
19. Ohbu, M.; Ogawa, K.; Konno, S.; Kanzaki, A.; Terada, K.; Sugiyama, T.; Takebayashi, Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human gastric carcinoma. Cancer Lett. 2003, 189 (1), 33-8. (Pubitemid 35351517)
20. Monte, M. J.; Ballestero, M. R.; Briz, O.; Perez, M. J.; Marin, J. J. Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J. Pharmacol. Exp. Ther. 2005, 315 (1), 24-35. (Pubitemid 41380494)
21. Steiner, E.; Holzmann, K.; Elbling, L.; Micksche, M.; Berger, W. Cellular functions of vaults and their involvement in multidrug resistance. Curr. Drug Targets 2006, 7 (8), 923-34.
22. Haas, S.; Merkelbach-Bruse, S.; Justenhoven, C.; Brauch, H.; Fischer, H. P. Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver. Pathol. Res. Pract. 2009, 205 (10), 716-25.
23. Smith, C. A.; Smith, G.; Wolf, C. R. Genetic polymorphisms in xenobiotic metabolism. Eur. J. Cancer 1994, 30A (13), 1921-35. (Pubitemid 24382590)
24. Howie, A. F.; Forrester, L. M.; Glancey, M. J.; Schlager, J. J.; Powis, G.; Beckett, G. J.; Hayes, J. D.; Wolf, C. R. Glutathione Stransferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis 1990, 11 (3), 451-8. (Pubitemid 20079399)
25. Monte, M. J.; Palomero, F.; Sainz, G. R.; Dominguez, M.; Diez, M.; Torano, A.; Marin, J. J. Bile acid secretion during rat liver carcinogenesis. Life Sci. 2000, 66 (12), 1085-95. (Pubitemid 30117775)
26. Peters, G. J.; Laurensse, E.; Leyva, A.; Lankelma, J.; Pinedo, H. M. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 1986, 46 (1), 20-8.
27. Ishitsuka, H.; Miwa, M.; Takemoto, K.; Fukuoka, K.; Itoga, A.; Maruyama, H. B. Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 1980, 71 (1), 112-23.
28. Tanimoto, K.; Kaneyasu, M.; Shimokuni, T.; Hiyama, K.; Nishiyama, M. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro. Pharmacogenet. Genomics 2007, 17 (1), 1-10. (Pubitemid 46183789)
29. Li, R.; Sirawaraporn, R.; Chitnumsub, P.; Sirawaraporn, W.; Wooden, J.; Athappilly, F.; Turley, S.; Hol, W. G. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. Mol. Biol. 2000, 295 (2), 307-23. (Pubitemid 30045362)
30. Oseini, A. M.; Roberts, L. R. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin. Ther. Targets 2009, 13 (4), 443-54.
31. Marijon, H.; Faivre, S.; Raymond, E. Targeted therapies in hepatocellular carcinomas: recent results and future development. Bull. Cancer 2009, 96 (5), 553-61.
32. Stock, P.; Monga, D.; Tan, X.; Micsenyi, A.; Loizos, N.; Monga, S. P. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol. Cancer Ther. 2007, 6 (7), 1932-41. (Pubitemid 47052483)
33. Watanuki, A.; Ohwada, S.; Fukusato, T.; Makita, F.; Yamada, T.; Kikuchi, A.; Morishita, Y. Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma. Anticancer Res. 2002, 22 (2B), 1113-9. (Pubitemid 34836159)
34. Wong, N.; Yeo, W.; Wong, W. L.; Wong, N. L.; Chan, K. Y.; Mo, F. K.; Koh, J.; Chan, S. L.; Chan, A. T.; Lai, P. B.; Ching, A. K.; Tong, J. H.; Ng, H. K.; Johnson, P. J.; To, K. F. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int. J. Cancer 2009, 124 (3), 644-52.
35. Delmastro, D. A.; Li, J.; Vaisman, A.; Solle, M.; Chaney, S. G. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. 1997, 39 (3), 245-53. (Pubitemid 26414263)
36. Ding, X.; Mohd, A. B.; Huang, Z.; Baba, T.; Bernardini, M. Q.; Lyerly, H. K.; Berchuck, A.; Murphy, S. K.; Buermeyer, A. B.; Devi, G. R. MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. Br. J. Cancer 2009, 101 (2), 269-77.
37. Fink, D.; Aebi, S.; Howell, S. B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. 1998, 4 (1), 1-6. (Pubitemid 28062870)
38. Melton, D. W.; Ketchen, A. M.; Nunez, F.; Bonatti-Abbondandolo, S.; Abbondandolo, A.; Squires, S.; Johnson, R. T. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J. Cell Sci. 1998, 111 (Part 3), 395-404. (Pubitemid 28097265)
39. Ormerod, M. G.; O'Neill, C.; Robertson, D.; Kelland, L. R.; Harrap, K. R. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. 1996, 37 (5), 463-71.
40. Segal-Bendirdjian, E.; Jacquemin-Sablon, A. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp. Cell Res. 1995, 218 (1), 201-12.
41. Bunz, F. Cell death and cancer therapy. Curr. Opin. Pharmacol. 2001, 1 (4), 337-41. (Pubitemid 33585981)
42. Peroukides, S.; Bravou, V.; Alexopoulos, A.; Varakis, J.; Kalofonos, H.; Papadaki, H. Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol. Histopathol. 2010, 25 (3), 299-307.
43. Augello, C.; Caruso, L.; Maggioni, M.; Donadon, M.; Montorsi, M.; Santambrogio, R.; Torzilli, G.; Vaira, V.; Pellegrini, C.; Roncalli, M.; Coggi, G.; Bosari, S. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 2009, 9, 125.